View More Recent Stories
-
Oppenheimer Reiterates Outperform Rating on Jasper Therapeutics (JSPR)
-
BTIG Reiterates Buy Rating on Jasper Therapeutics (JSPR)
-
TD Cowen Reiterates Buy Rating on Jasper Therapeutics (JSPR)
-
Jasper Therapeutics (JSPR) Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
-
Oppenheimer Reiterates Outperform Rating on Jasper Therapeutics (JSPR)
-
Jasper Therapeutics (JSPR) Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
-
JMP Securities Starts Jasper Therapeutics (JSPR) at Market Outperform
-
H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)
-
Jasper Therapeutics (JSPR) PT Lowered to $68 at RBC Capital
-
Jasper Therapeutics (JSPR) Tops Q2 EPS by 12c
-
TD Cowen Reiterates Buy Rating on Jasper Therapeutics (JSPR)
-
2Q24 U.S. biotech earnings preview
-
BTIG Starts Jasper Therapeutics (JSPR) at Buy
-
Stifel Starts Jasper Therapeutics (JSPR) at Buy
-
Oppenheimer Reiterates Outperform Rating on Jasper Therapeutics (JSPR)

